Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Atrasentan · Vanrafia

Small molecule · Antagonist of endothelin type A receptor (EDNRA) · developed by Novartis

Approved FDA, Apr 2025
NVS Developer

What is Atrasentan?

Atrasentan is an endothelin receptor antagonist that binds the endothelin type A receptor with high selectivity over the endothelin type B receptor. It is studied in IgA nephropathy, a kidney disease in which endothelin-1 is thought to contribute to pathogenesis through the endothelin type A receptor.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Vanrafia
Drug type
Small molecule
Targets
endothelin type A receptor (EDNRA)
Mechanism
Antagonist of endothelin type A receptor (EDNRA)
Therapy area
Renal & urology
Developer
Novartis (NVS)
FDA status
Approved as Vanrafia (April 2, 2025), NDA219208 · FDA label
UNII
V6D7VK2215

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 12, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Berger DiseaseBergers DiseaseIgA NephropathyImmunoglobulin A NephropathyNephritis IgA Type, Nephropathy IgA TypePrimary IgAN

Other drugs acting on EDNRA

More from Novartis

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Atrasentan

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.